Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Rubius Therapeutics history
Rubius Therapeutics company history timeline
Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary.
Since 2014, Dannielle held positions of increasing responsibility in global supply chain, strategy and operational excellence across several divisions within Novartis.
In 2016, Jessica pursued her entrepreneurial interests and built both a network marketing business in health and wellness and her own consulting business providing start-up biotech companies with clinical development expertise until joining Rubius.
Life Science Cares (LSC) Boston was founded in 2016 to provide a platform for companies and their employees to make a difference.
Before joining Rubius in 2018, Pablo served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer.
Jill Murray joined Rubius in 2019 as an HR Business Partner.
In 2020, Gilead Sciences secured an exclusive option to acquire Tizona for up to $1.5 billion.
James “Jim” Jogerst joined Rubius as Chief Business Officer in August of 2021, bringing more than 20 years of experience in developing, structuring and closing high-level deals, including mergers and acquisitions, business development and licensing transactions.
Director, HR Business Partner and Head of Total Rewards in 2021 and now serves as Vice President and Head of Human Resources.
Rate how well Rubius Therapeutics lives up to its initial vision.
Rubius Therapeutics jobs
Do you work at Rubius Therapeutics?
Is Rubius Therapeutics' vision a big part of strategic planning?
Rubius Therapeutics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Axcella | 2010 | $8.5M | 59 | - |
| Leap Therapeutics | 2011 | $1.5M | 30 | - |
| Abeona Therapeutics | 1989 | $1.4M | 83 | 8 |
| Endonovo Therapeutics | 2011 | $165,796 | 1 | - |
| Evelo Biosciences | 2015 | $11.3M | 75 | - |
| Eidos Therapeutics | 2013 | $26.7M | 20 | - |
| Cabaletta Bio | 2017 | $1.6M | 20 | 10 |
| CAMP4 Therapeutics | 2016 | $890,000 | 46 | 4 |
| Prevail Therapeutics | 2017 | $74.3M | 66 | - |
| Codiak BioSciences | 2015 | $22.9M | 115 | - |
Rubius Therapeutics history FAQs
Zippia gives an in-depth look into the details of Rubius Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Rubius Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Rubius Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Rubius Therapeutics. The data presented on this page does not represent the view of Rubius Therapeutics and its employees or that of Zippia.
Rubius Therapeutics may also be known as or be related to RUBIUS THERAPEUTICS, INC., Rubius Therapeutics, Rubius Therapeutics Inc and Rubius Therapeutics, Inc.